ProCE Banner Activity

CE / CME

Advances in CDK4/6 Inhibition in EBC: Expert Guidance and Case Challenges for the Multidisciplinary Team

Video

Join expert faculty as they discuss current trends, challenges, and advances in the field of CDK4/6 inhibition in patients with early breast cancer.  

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: March 07, 2024

Expiration: March 06, 2025

Share

Faculty

Joyce O'Shaughnessy

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Texas Oncology
Sarah Cannon Research Institute
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC, in partnership with Breastcancer.org and Smart Patients Inc.

ProCE Banner

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation

Partners

Breastcancer.org

ProCE Banner

Smart Patients

ProCE Banner

Target Audience

This program is intended for oncologists, surgeons/surgical oncologists, pathologists, radiologists, pharmacists, nurse practitioners, physician associates, oncology nurses, and other healthcare professionals on the multidisciplinary team who care for patients with breast cancer.

Program Learning Goal

The goal of this program is to improve the knowledge, confidence, and competence of learners in applying current data on the use of CDK4/6 inhibitors as part of their care of patients with early-stage breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients who may benefit from the addition of CDK4/6 inhibitor therapy to endocrine therapy in the adjuvant setting

  • Plan evidence-based personalized treatment strategies for HR-positive/HER2-negative early breast cancer, fostering collaborative discussions and workflows among the oncology multidisciplinary team

  • Develop strategies that promote optimal adherence and persistence to prescribed oral CDK4/6 inhibitors in patients with early-stage breast cancer

  • Manage adverse events associated with oral targeted therapy in the adjuvant setting for patients with HR-positive/HER2-negative breast cancer

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Texas Oncology
Sarah Cannon Research Institute
Dallas, Texas

Joyce O'Shaughnessy, MD: consultant/advisor/speaker: AbbVie, Agendia, Aptitude Health, AstraZeneca, Bayer, Bristol Myers Squibb, Caris, Carrick Therapeutics, Celgene, Daiichi Sankyo, Eisai, Exact Sciences, Fishawack Health, G1 Therapeutics, GlaxoSmithKline, Genentech, Gilead Sciences, Immunomedics, Incyte Corporation, Lilly, Loxo Oncology, Merck, Novartis, Ontada, Pfizer, Pharmacyclics, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Prime Oncology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Theralink, Synthon, Veru.

The planners and content peer reviewers from Clinical Care Options, LLC, Breastcancer.org, and Smart Patients do not have any do not have any relevant financial relationships to disclose, except Julia A. LaBarbera, MSN, RN, AGACNP-BC, as noted below.

Julia A. LaBarbera, MSN, RN, AGACNP-BC: consultant/advisor/speaker: Astra Zeneca, Daiichi Sankyo.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 07, 2024, through March 06, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-24-077-H01-P 

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until March 06, 2025. PAs should only claim credit commensurate with the extent of their participation.